Determine the necessary mass, volume, or concentration for preparing a solution.
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC 50 s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively
In Vitro
IMR-687 inhibits PDE9A with more than 800-fold greater potency than PDE1A3, PDE1B, PDE1C, PDE5A2, with IC 50 values of 88.4 μM, 8.48 μM, 12.2 μM, and 81.9 μM, respectively. IMR-687 (0.1-10 μM) treatment in erythroid K562 cells for 72 hours induces hemoglobin (HbF) in a dose-dependent manner. IMR-687 (0.03-10 μM) treatment for 6 hours in erythroid K562 cells increases cGMP in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
IMR-687 (30 mg/kg/day; after 30 days of treatment) shows a greater than 3-fold in the percent of HbF + F-cells (8.4% in vehicle treated and 27.3% in IMR-687 treated) and a corresponding 2-fold decrease in sickled red blood cells (56.3% in vehicle treated and 24.4% in IMR-687 treated) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HbSS-Townes mice on a 129/B6 background (10-12 weeks old) Dosage: 30 mg/kg Administration: Dosed daily by gavage for 30 days Result: Resulted in fetal hemoglobin (HbF) induction, reduced hemolysis and reduced reticulocytosis.
Form:Solid
IC50& Target:PDE9A1 8.19 nM () PDE9A2 9.99 nM () PDE1A3 88.4 nM () PDE1B 8.48 nM () PDE1C 12.2 nM () PDE5A2 81.9 nM ()
| ALogP | 0.4 |
|---|
| Canonical Smiles | CC1CN(CC1C2=CN3C(=CN=C3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5 |
|---|---|
| IUPAC Name | 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-(oxan-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one |
| InChIKey | GWGNPYYVGANHRJ-GDBMZVCRSA-N |
| INCHI | 1S/C21H26N6O2/c1-14-10-26(13-19-22-5-2-6-23-19)11-16(14)17-12-27-18(21(28)25-17)9-24-20(27)15-3-7-29-8-4-15/h2,5-6,9,12,14-16H,3-4,7-8,10-11,13H2,1H3,(H,25,28)/t14-,16-/m1/s1 |
| Isomeric SMILES | C[C@@H]1CN(C[C@H]1C2=CN3C(=CN=C3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5 |
| Alternate CAS | 2062661-53-2 |
| PubChem CID | 124220601 |
| Molecular Weight | 394.47 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Imidazo[1,5-a]pyrazines |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Imidazo[1,5-a]pyrazines |
| Alternative Parents | Aralkylamines Pyrimidines and pyrimidine derivatives Pyrazines Oxanes N-substituted imidazoles N-alkylpyrrolidines Heteroaromatic compounds Trialkylamines Lactams Oxacyclic compounds Dialkyl ethers Azacyclic compounds Organopnictogen compounds Organic oxides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Imidazo[1,5-a]pyrazine - Aralkylamine - N-alkylpyrrolidine - Pyrimidine - Pyrazine - Oxane - N-substituted imidazole - Heteroaromatic compound - Pyrrolidine - Imidazole - Azole - Tertiary aliphatic amine - Tertiary amine - Lactam - Oxacycle - Azacycle - Ether - Dialkyl ether - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Amine - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as imidazo[1,5-a]pyrazines. These are aromatic heteropolycyclic compounds containing an imidazole ring fused to and sharing one nitrogen with a pyrazine ring. |
| External Descriptors | Not available |
| Solubility | DMSO : 100 mg/mL (253.50 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 394.500 g/mol |
| XLogP3 | 0.400 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 394.212 Da |
| Monoisotopic Mass | 394.212 Da |
| Topological Polar Surface Area | 85.200 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 631.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |